BS_QW60M0FE
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 79.73061760840999
- age_years
- 10.671
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.512
- ALLOGRAFT_REJECTION+0.472
- INTERFERON_GAMMA_RESPONSE+0.422
- PI3K_AKT_MTOR_SIGNALING+0.348
- NOTCH_SIGNALING+0.315
- INFLAMMATORY_RESPONSE+0.281
- IL6_JAK_STAT3_SIGNALING+0.275
- APICAL_SURFACE+0.270
- DNA_REPAIR+0.244
- TGF_BETA_SIGNALING+0.238
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- PANCREAS_BETA_CELLS-0.242
- SPERMATOGENESIS-0.194
- CHOLESTEROL_HOMEOSTASIS-0.155
- MTORC1_SIGNALING-0.141
- KRAS_SIGNALING_DN-0.136
- KRAS_SIGNALING_UP-0.048
- UV_RESPONSE_UP-0.046
- ANDROGEN_RESPONSE-0.035
- FATTY_ACID_METABOLISM-0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_A3QZB9Y2 | Meningioma | — | 0.921 |
| 2 | BS_W72364MN | Meningioma | — | 0.893 |
| 3 | BS_X2QTK3QD | Meningioma | — | 0.838 |
| 4 | BS_JGPR9SR2 | Meningioma | — | 0.832 |
| 5 | BS_Z9ZS6ZS2 | MPNST | — | 0.812 |
| 6 | BS_Y3G1X98S | Meningioma | — | 0.807 |
| 7 | SRR934745 | — | — | 0.805 |
| 8 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.802 |
| 9 | BS_8NY9J9NQ | Meningioma | — | 0.800 |
| 10 | SJBT031026_D3.RNA-Seq | EPN | Spinal EPN | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.512 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.472 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.422 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.348 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.315 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.281 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.275 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.244 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.238 | Inavolisib | — uncovered |
| APOPTOSIS | 0.219 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.206 | Idelalisib | — uncovered |
| COAGULATION | 0.189 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.187 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.185 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.177 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.158 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.153 | Inavolisib | — uncovered |
| COMPLEMENT | 0.151 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |